Article Menu
Need Help?
No Article Versions Notes Found
Cite
Armoiry, X.; Spath, H.-M.; Clarke, A.; Connock, M.; Sutcliffe, P.; Dussart, C. Comparison of Health Technology Assessment for New Medicines in France and England: An Example Based on Ixazomib for Patients with Relapsed or Refractory Multiple Myeloma. J. Mark. Access Health Policy 2019, 7, 1648971. https://doi.org/10.1080/20016689.2019.1648971
Armoiry X, Spath H-M, Clarke A, Connock M, Sutcliffe P, Dussart C. Comparison of Health Technology Assessment for New Medicines in France and England: An Example Based on Ixazomib for Patients with Relapsed or Refractory Multiple Myeloma. Journal of Market Access & Health Policy. 2019; 7(1):1648971. https://doi.org/10.1080/20016689.2019.1648971
Chicago/Turabian StyleArmoiry, Xavier, Hans-Martin Spath, Aileen Clarke, Martin Connock, Paul Sutcliffe, and Claude Dussart. 2019. "Comparison of Health Technology Assessment for New Medicines in France and England: An Example Based on Ixazomib for Patients with Relapsed or Refractory Multiple Myeloma" Journal of Market Access & Health Policy 7, no. 1: 1648971. https://doi.org/10.1080/20016689.2019.1648971
APA StyleArmoiry, X., Spath, H.-M., Clarke, A., Connock, M., Sutcliffe, P., & Dussart, C. (2019). Comparison of Health Technology Assessment for New Medicines in France and England: An Example Based on Ixazomib for Patients with Relapsed or Refractory Multiple Myeloma. Journal of Market Access & Health Policy, 7(1), 1648971. https://doi.org/10.1080/20016689.2019.1648971
